



Ref: JSTL/BOD/BSE/2023-24/Nov23

Date: November 13, 2023

**To,
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 538837)**

Dear Sir / Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Outcome of Board Meeting for the quarter and half year ended 30.09.2023 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the exchange that the Board of Directors of Jeevan Scientific Technology Limited at its meeting held on Monday, the 13th day of November, 2023 at 03:00 P.M. at registered office of the Company for the quarter and half year ended 30.09.2023 considered and approved the following:

1. Un- Audited Financial Results (standalone and consolidated) for the quarter and half year ended 30.09.2023. **(Attached)**
2. Limited Review Report (standalone and consolidated) for the Quarter and half year ended 30.09.2023. **(Attached)**

The meeting concluded at 5.00 P.M.

This is for the information and records of the Exchange, please.

Thanking You,
Yours faithfully,
For Jeevan Scientific Technology Limited

**Krishna Kishore Kuchipudi
Vice Chairman and Managing Director
(DIN: 00876539)**

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sar Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of unaudited standalone financial results for the quarter and half year ended 30 September 2023

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended		Half year ended		Half year ended		Year Ended March 2023 Audited
	Quarter ended 30 September 2023 Unaudited	30 June 2023 Unaudited	Quarter ended 30 September 2022 Unaudited	30 September 2023 Unaudited	Half year ended 30 September 2022 Unaudited	Half year ended 30 September 2022 Unaudited	
I Income from operations							
(a) Net sales / income from operations	806.49	1,038.91	797.33	1,845.40	1,830.12	3,617.80	
(b) Other Income	25.65	29.51	30.70	55.16	52.16	106.19	
III Total income (I+II)	832.14	1,068.42	828.03	1,900.55	1,882.28	3,723.99	
IV Expenses							
(a) Cost of materials consumed	89.01	92.44	58.45	181.45	99.37	245.54	
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	54.65	54.65	
(c) Employee benefits expense	388.56	368.97	362.88	757.53	664.73	1,486.56	
(d) Finance costs	24.68	19.29	21.81	43.98	49.00	94.76	
(e) Depreciation and amortisation expense	137.57	142.01	126.13	279.58	231.43	502.36	
(f) Other expenses	261.77	372.82	417.42	634.59	924.31	1,701.97	
Total Expenses	901.60	995.53	986.69	1,897.13	2,023.49	4,085.84	
V Profit/ (Loss) before Tax (III-IV)	(69.46)	72.89	(158.66)	3.43	(141.21)	(361.85)	
VI Tax Expenses							
a. Current tax	0.53	-	-	0.53	-	-	
b. Adjustment of tax relating to earlier period	-	-	-	-	-	49.55	
c. Deferred tax	(19.75)	14.60	(39.55)	(5.15)	(60.41)	(111.10)	
Total tax expense	(19.22)	14.60	(39.55)	(4.62)	(60.41)	(61.55)	
VIII Profit/(Loss) for the period/year (V-VI)	(50.24)	58.28	(119.11)	8.05	(80.80)	(300.30)	
VIII Other Comprehensive Income							
A (i) Items that will not be reclassified subsequently to profit or loss	(2.90)	-	(7.46)	(2.90)	(6.59)	(11.49)	
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	0.81	-	-	0.81	-	2.89	
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-	
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
Total other comprehensive income/(loss) for the period	(2.10)	-	(7.46)	(2.10)	(6.59)	(8.60)	
Total Comprehensive Income for the period (VII+VIII)	(52.33)	58.28	(126.57)	5.95	(87.39)	(308.90)	
IX Total Comprehensive Income for the period (VII+VIII)	(52.33)	58.28	(126.57)	5.95	(87.39)	(308.90)	



X	Paid Up equity share capital (Face value of Rs.10/- each)	1,548.02	1,548.02	1,530.15	1,548.02	1,530.15	1,548.02
XI	Other equity	-	-	-	-	-	3,283.58
XII	Earnings per equity share (of Rs. 10/- each) (not annualised for the quarters)						
	a) Basic	(0.32)	0.38	(0.78)	0.05	(0.53)	(1.96)
	b) Diluted	(0.32)	0.36	(0.78)	0.05	(0.53)	(1.96)

Notes to the unaudited financial results

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The above unaudited results have been reviewed by the Audit Committee at its meeting held on 13 November 2023 of the board and approved by the Board of Directors of the Company at their meeting held on 13 November 2023
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
- Employee benefit expenses for the Quarter ending 30 September includes Rs. 37.85 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the Quarter and half year ended 30 September 2023 are also available on website of BSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to confirm to the current period presentation.

for Jeevan Scientific Technology Limited

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN:00876539)



Place: Hyderabad.

Date: 13 November 2023

Jeevan Scientific Technology Limited CIN:L72200TG1999PLC031016 Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008. Standalone Balance Sheet as at 30 September 2023 (Amount in Indian rupees lakhs, except share data and where otherwise stated)		
Particulars	As at 30 September 2023	As at 31 March 2023
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	1,463.97	1,550.26
b) Other intangible assets	563.53	603.58
c) Right of use assets	187.69	249.24
d) Financial Assets		
i)Investments	200.00	200.00
ii)Other financial assets	58.16	56.41
e) Other non current assets	1,207.54	857.54
f) Deferred tax asset (net)	69.92	63.95
(2)Current Assets		
a) Inventories	91.68	87.16
b) Financial Assets		
i) Trade receivables	974.25	1,168.19
ii) Cash and cash equivalents	633.92	612.25
iii)Other financial assets	232.44	527.90
c) Current tax assets (net)	370.19	275.37
d) Other current assets	218.48	123.82
Total	6,271.78	6,375.66
Equity and Liabilities		
Equity		
a) Equity Share Capital	1,548.02	1,548.02
b) Other Equity	3,365.24	3,283.58
Liabilities		
(1)Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	257.06	321.35
(ii) Lease liabilities	85.29	148.17
b) Provisions	38.86	30.95
(2)Current Liabilities		
a)Financial liabilities		
i) Borrowings	234.10	292.67
ii) Lease liabilities	126.14	121.68
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	81.67	69.14
(b) Total Outstanding dues of creditors other than micro, small and medium enterprises	87.85	193.76
iv) Other financial liabilities	102.35	103.11
b) Other current liabilities	336.68	262.13
c) Provisions	8.53	1.10
d) Current tax liabilities (net)	-	-
Total	6,271.78	6,375.66

for Jeevan Scientific Technology Limited

K. Krishna Kishore

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)



Place: Hyderabad
Date: 13.11.2023

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Standalone Cash flow statement for the period ended 30 September 2023

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	For the Half Year ended 30 September 2023	For the year ended 31 March 2023
A.	Cash flow from operating activities		
	Net Profit/(loss) before tax	3.43	(361.86)
	Adjustments for:		
	Depreciation and amortisation expenses	279.58	502.36
	Dividend received	(7.10)	(10.50)
	Interest received	(24.01)	(83.19)
	Share based payments to employees	75.71	247.94
	Net foreign exchange loss/(gain)	(20.40)	(2.85)
	Finance cost	40.52	94.76
	Operating profit before working capital changes	347.72	386.66
	Changes in Working Capital		
	Inventories	(4.53)	58.40
	Trade receivables	214.35	(404.36)
	Current and non current financial assets	293.71	245.35
	Other current and non current assets	(94.66)	136.99
	Trade payables	(93.38)	62.69
	Other financial liabilities	(0.77)	(223.94)
	Other liabilities	74.54	(112.15)
	Provisions	11.90	(503.02)
	Cash generated from operations before Tax	748.89	(353.37)
	Taxes Paid	(94.83)	(275.37)
	Net cash from operating activity	654.06	(628.74)
B.	Cash flow from investing activities		
	Purchase of property, plant and equipment including capital advances and capital creditors	(441.70)	(625.92)
	Investment in subsidiaries	-	(200.00)
	Dividend Received	7.10	10.50
	Investments in fixed deposits and margin money deposits with bank	-	5.24
	Interest Received	24.01	83.19
	Net cash used in investing activity	(410.60)	(727.00)
C.	Cash flow from financing activity		
	Repayment of non current borrowings	(56.47)	(244.97)
	Repayment of current borrowings	(66.39)	(395.40)
	Interest paid	(40.52)	(94.76)
	Dividend paid	-	(183.62)
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	-	17.88
	Repayment of principle portion of lease liability	(58.41)	(102.48)
	Net cash generated in financing activity	(221.79)	(1,003.35)
	Net increase in cash and cash equivalents (A+B+C)	21.68	(2,359.09)
	Cash and cash equivalents at the beginning of the year/period	612.25	2,971.33
	Cash and cash equivalents at the end of the year/period	633.92	612.25

for Jeevan Scientific Technology Limited

Place: Hyderabad
Date: 13.11.2023K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of unaudited consolidated financial results for the quarter and half year ended 30 September 2023

All amounts are in Indian Rupees in Lakh

Particulars	Quarter Ended		Half year ended		Year Ended	
	Quarter ended 30 September 2023	Quarter ended 30 June 2023	Quarter ended 30 September 2022	Half year ended 30 September 2023		Half year ended 30 September 2022
I Income	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
(a) Net sales/Income from operations	806.49	1,038.91	797.33	1,845.40	1,830.12	3,617.80
(b) Other Income	25.84	29.75	30.70	55.59	52.16	107.42
III Total income (I+II)	832.33	1,068.66	828.03	1,900.99	1,882.28	3,725.22
IV Expenses						
(a) Cost of materials consumed	89.01	92.44	58.45	181.45	99.37	245.54
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	54.65	54.65
(c) Employee benefits expense	389.01	369.10	362.88	758.12	664.73	1,486.58
(d) Finance costs	26.43	22.82	21.81	49.26	49.00	97.21
(e) Depreciation and Amortisation expense	142.53	146.97	126.13	289.50	231.43	507.32
(f) Other Expenses	268.33	374.53	417.42	642.86	924.31	1,702.18
Total Expenses	915.32	1,005.87	986.69	1,921.18	2,023.49	4,093.48
V Profit/ (Loss) before tax (III-IV)	(82.99)	62.79	(158.66)	(20.20)	(141.21)	(368.26)
VI Tax expenses						
a. Current tax	0.53	-	-	0.53	-	-
b. Earlier tax	-	-	-	-	-	49.55
c. Deferred tax	(22.10)	12.13	(39.55)	(9.97)	(60.41)	(111.34)
VIII Profit/(Loss) for the period/year	(61.42)	50.66	(119.11)	(10.76)	(80.80)	(306.47)




VIII	Other Comprehensive Income								
	A	(i) Items that will not be reclassified subsequently to profit or loss	(2.90)	-	(7.46)	(2.90)	(6.59)	(11.49)	
		(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	0.81	-	-	0.81	-	2.89	
	B	(i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-	
		(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
		Comprehensive Income for the period /year	(2.10)	-	(7.46)	(2.10)	(6.59)	(8.60)	
IX		Total Comprehensive Income for the period /year	(63.51)	50.66	(126.57)	(12.85)	(87.39)	(315.07)	
X		Paid Up Equity Share Capital (Face Value of Rs.10/- each	1,548.02	1,548.02	1,530.15	1,548.02	1,530.15	1,548.02	
XI		Other equity excluding revaluation reserve	-	-	-	-	-	3,270.94	
XII		Earnings per Equity share							
		a) Basic (Amount in Rupees)	(0.39)	0.33	(0.78)	(0.07)	(0.53)	(2.00)	
		b) Diluted (Amount in Rupees)	(0.39)	0.32	(0.78)	(0.07)	(0.53)	(2.00)	
XIII		Net profit attributable to:							
		Owners of the company	(60.18)	51.51	(119.11)	(8.67)	(80.80)	(305.74)	
		Non-Controlling interest	(1.24)	(0.85)	-	(2.09)	-	(0.73)	
XIV		Other comprehensive income attributable to:							
		Owners of the company	(2.10)	-	(7.46)	(2.10)	(6.59)	(8.60)	
		Non-Controlling interest	-	-	-	-	-	-	
XV		Total comprehensive income attributable to:							
		Owners of the company	(62.27)	51.51	(126.57)	(10.76)	(87.39)	(314.34)	
		Non-Controlling interest	(1.24)	(0.85)	-	(2.09)	-	(0.73)	



Notes to the unaudited financial results

- 1 The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- 2 The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 13 November 2023.
- 3 The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015
- 4 Employee benefit expenses for the Quarter ending 30 September 2023 includes Rs.37.85 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- 5 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
- 6 The results for the Quarter ended 30 September 2023 are also available on website of BSE Limited and on the Company's website.
- 7 Figures for the previous periods have been rearranged/ reclassified wherever necessary to confirm to the current period presentation.

for Jeevan Scientific Technology Limited


K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)




Place:Hyderabad.

Date:13 November 2023

Jeevan Scientific Technology Limited		
CIN:L72200TG1999PLC031016		
Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.		
Consolidated Balance Sheet as at 30 September 2023		
(Amount in Indian rupees lakhs, except share data and where otherwise stated)		
Particulars	As at 30 September 2023	As at 31 March 2023
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	1,463.97	1,550.26
b) Other intangible assets	563.53	603.58
c) Capital work in progress	551.37	190.36
d) Right of use assets	272.01	343.47
e) Financial Assets		
i)Other financial assets	67.18	64.03
f) Other non current assets	1,207.54	857.54
g) Deferred tax asset (net)	74.97	64.19
(2)Current Assets		
a) Inventories	94.45	87.16
b) Financial Assets		
i) Trade receivables	1,022.04	1,168.19
ii) Cash and cash equivalents	645.19	683.38
iii)Other financial assets	232.44	527.90
c) Current tax assets (Net)	370.28	275.46
d) Other current assets	310.21	176.76
Total	6,875.20	6,592.29
Equity and Liabilities		
Equity		
a) Equity share capital	1,548.02	1,548.02
b) Other equity	3,335.88	3,270.94
Total equity	4,883.91	4,818.96
Non controlling interest	21.28	23.37
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	697.97	351.35
(ii) Lease liabilities	157.69	228.70
b) Provisions	38.86	30.95
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	234.10	292.67
ii) Lease liabilities	142.02	136.79
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	87.42	69.14
(b) Total outstanding dues of Creditors other than micro,small and medium enterprises	92.93	196.41
iv) Other financial liabilities	117.53	177.18
b) Other current liabilities	392.96	265.66
c) Provisions	8.53	1.10
Total	6,875.20	6,592.29

for Jeevan Scientific Technology Limited


K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)


Pale: Hyderabad
Date: 13.11.2023



Jeevan Scientific Technology Limited			
CIN:L72200TG1999PLC031016			
Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.			
Consolidated Cash flow statement for the period ended 30 September 2023			
(Amount in Indian rupees lakhs, except share data and where otherwise stated)			
S.No	Particulars	For the period ended 30 September 2023	For the year ended 31 March 2023
A.	Cash flow from operating activities		
	Net Profit/(loss) before tax	(20.20)	(368.27)
	Adjustments for:		
	Depreciation and amortisation expenses	289.50	507.32
	Adjustments on account of fair value measurement of lease deposits	-	(4.68)
	Dividend received	(7.10)	(10.50)
	Interest received	(24.05)	(84.10)
	Net foreign exchange loss/(gain)	(20.40)	(2.85)
	Share based payments to employees	75.71	247.94
	Finance cost	45.15	97.21
	Operating profit before working capital changes	338.60	382.06
	Changes in working capital		
	Inventories	(7.30)	58.40
	Trade receivables	166.56	(404.36)
	Current and non current financial assets	292.32	237.73
	Other current and non current assets	(133.45)	75.78
	Trade payables	(85.20)	50.16
	Other financial liabilities	(59.64)	(149.88)
	Other liabilities	127.30	(112.04)
	Provisions	11.90	(503.02)
	Cash generated from operations before tax	651.08	(365.15)
	Taxes Paid	(94.83)	(275.37)
	Net cash from operating activity	556.25	(640.52)
B.	Cash flow from investing activities		
	Purchase of property, plant and equipment including capital advances and capital creditors	(802.71)	(816.28)
	Investments in fixed deposits and margin money deposits with banks	-	5.24
	Dividend Received	7.10	10.50
	Acquisition of a subsidiary, net of cash acquired	-	23.35
	Interest received	24.05	84.10
	Net cash used in investing activity	(771.56)	(693.09)
C.	Cash flow from financing activity		
	Proceeds from /(Repayment) of non current borrowings	346.62	(71.21)
	Proceeds from /(Repayment) of current borrowings	(58.57)	(539.16)
	Interest paid	(45.15)	(97.21)
	Dividend paid	-	(183.62)
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	-	42.88
	Repayment of principle portion of lease liability	(65.78)	(106.03)
	Net cash generated in financing activity	177.12	(954.35)
	Net increase in cash and cash equivalents (A+B+C)	(38.18)	(2,287.96)
	Cash and cash equivalents at the beginning of the year/period	683.38	2,971.33
	Cash and cash equivalents at the end of the year/period	645.19	683.38

for Jeevan Scientific Technology Limited

Pale: Hyderabad
Date: 13.11.2023


K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

**TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent Company"), for the quarter and half year ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co
Chartered Accountants
Firm Reg. No: 012194S



CA N RAJESH
Partner
M. No: 223169



Place : Hyderabad

Date :13/11/2023

UDIN # 23223169BGVJYY8396



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Parent") and its subsidiary (the Parent and Subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The consolidated unaudited financial results includes the interim financial results of subsidiary company M/s Nayas Laboratories Private Limited. These unaudited financial results and other unaudited financial information have been furnished to us by the management and have been reviewed by us.

**PAVULURI & Co.**

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,
Sucasa, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639 / 2640
Email : pavuluriandco@gmail.com

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co
Chartered Accountants
Firm Reg. No: 012194S

N. Rajesh

CA N RAJESH
Partner
M. No: 223169



Place : Hyderabad

Date :13/11/2023

UDIN # 23223169BGVJYX1248